Author: admin

RoarFun Enhances Conference Engagement with Innovative VR Motion Flight Simulator at Aviation Carbon 2024

RoarFun proudly delivered cutting-edge entertainment and engagement solutions at Aviation Carbon 2024, held at the London Heathrow Marriott Hotel. Partnering with a leading participant of the conference, RoarFun provided its state-of-the-art VR Motion Flight Simulator, transforming their exhibition stand into a must-visit destination for attendees.

Designed to captivate and educate, the flight simulator experience incorporated the participant’s branding and sustainability messaging, creating an immersive environment that aligned with the conference’s focus on decarbonizing the aviation industry. Visitors to the stand were offered a unique opportunity to experience flight in a virtual setting while learning about the participant’s innovative approaches to reducing carbon emissions.

Over the two-day event, participants received brief educational sessions on primary flight controls before engaging in a simulated takeoff from London Heathrow Airport. Utilizing a motion platform replicating the movements of a Boeing 737-800 and a high-fidelity VR headset, the experience provided a realistic cockpit environment. Each session lasted 7-10 minutes, during which attendees took off, ascended to 5,000 feet, and executed an emergency landing back at Heathrow, all under the guidance of experienced support staff.

“We are thrilled to have supported one of the conference’s key participants by enhancing their presence with our VR Motion Flight Simulator hire,” said Lukas Skalka – Technology Specialist. “Our aim is to create unforgettable, impactful experiences that not only engage audiences but also amplify our clients’ messages and values.”

The collaboration reflects RoarFun’s expertise in combining advanced virtual reality technology with tailored branding solutions to maximize engagement at high-profile events. The VR Motion Flight Simulator seamlessly blended entertainment with education, helping the participant attract significant attention and stand out in a competitive environment.

RoarFun’s commitment to innovation continues to empower brands to create meaningful connections with their audiences, even in complex industries like aviation. By integrating technology and storytelling, RoarFun delivers dynamic solutions that elevate event experiences and drive impactful communication. To rent racing and flight simulators with virtual branding integration become a powerful tool for marketing/PR managers at conferences and EXPOs worldwide.

For more information about RoarFun’s motion simulators, VR, virtual marketing solutions and event services, visit RoarFun’s website link.

Media Contact
Company Name: RoarFun
Contact Person: Lukas Skalka
Email: Send Email
Country: Czech Republic
Website: https://roarfun.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: RoarFun Enhances Conference Engagement with Innovative VR Motion Flight Simulator at Aviation Carbon 2024

Postpartum Depression Therapeutics Market Size in the 7MM was ~USD 260 Million in 2023, is expected to grow by 2034, and estimates DelveInsight

DelveInsight’s “Postpartum Depression Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Postpartum Depression, historical and forecasted epidemiology as well as the Postpartum Depression market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

 

Explore the intricate details of the Postpartum Depression Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Postpartum Depression Market Forecast. Click here to stay ahead in healthcare innovation @ Postpartum Depression Market Size

 

Key Takeaways from the Postpartum Depression Market Research Report

  • Among the seven major countries, the total Postpartum Depression diagnosed prevalence cases were ~1,310,000, in 2023.
  • In EU4 and the UK, the total Postpartum Depression diagnosed prevalence cases were ~4,60,000 in 2023.
  • In the seven major market, the United States accounted for the highest number of Postpartum Depression diagnosed cases (~720,000), followed by the UK, in 2023.
  • In Japan, the total Postpartum Depression diagnosed prevalent cases were ~126,000 in 2023.
  • The leading Postpartum Depression Companies such as Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, and others.
  • Promising Postpartum Depression Pipeline Therapies such as SAGE-217/BIIB-125, Ganaxolone, LPCN 1154, BRII-296, and others.

 

Discover which therapies are expected to grab the Postpartum Depression Market Share @ Postpartum Depression Market Outlook

 

Postpartum Depression Epidemiology Segmentation in the 7MM

• Total Postpartum Depression Diagnosed Prevalent Population of Maternal

 

Download the report to understand which factors are driving Postpartum Depression epidemiology trends @ Postpartum Depression Prevalence

 

Postpartum Depression Marketed Therapies

 

  • ZURZUVAE (zuranolone) : Sage Therapeutics/Biogen

Zuranolone (SAGE-217) is an investigational, oral, novel medicine in development for postpartum depression (PPD). It is given once daily, a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders, including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain, and the central nervous system (CNS) significantly regulates CNS function. SAGE-217 has been optimized for selectivity to synaptic and extrasynaptic type a γ-aminobutyric acid (GABAA) receptors and a pharmacokinetic profile for daily oral dosing.

 

  • ZULRESSO: Sage Therapeutics

ZULRESSO is a proprietary IV formulation of brexanolone. Brexanolone is chemically identical to allopregnanolone, a naturally occurring neuroactive steroid that acts as a positive allosteric modulator of gamma-aminobutyric acid (GABA) receptors indicated for treating PPD in adults. Brexanolone is available to patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility. In addition, patients must be monitored continuously during the drug infusion due to the risk of serious side effects. Notably, ZULRESSO (brexanolone) is the first drug approved by the US FDA specifically for PPD in adults. The mechanism of action of brexanolone in treating PPD in adults is related to its positive allosteric modulation of GABAA receptors. Brexanolone potentiated GABA-mediated currents from recombinant human GABAA receptors in mammalian cells expressing α1β2γ2 receptor subunits, α4β3δ receptor subunits, and α6β3δ receptor subunits.

 

Postpartum Depression Emerging Therapies

  • Ganaxolone: Marinus Pharmaceuticals

Ganaxolone (CCD-1042) is a lead clinical-stage drug candidate that brings a GABAA receptor modulating mechanism and an extensive safety database with exhibited anti-epileptic (antiseizure), anxiolytic (anti-anxiety) and anti-depressive activity in development by Marinus Pharmaceuticals. It is being developed in three different dosage forms (IV, capsule, and liquid) to maximize therapeutic reach to adult and pediatric patients in acute and chronic care settings with severe PPD. Unlike benzodiazepines, ganaxolone exhibits antiseizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors. Ganaxolone has been designed with an added methyl group that prevents back conversion to an active steroid, which unlocks ganaxolone’s potential for chronic use. In preclinical studies, ganaxolone exhibited potency and efficacy comparable to allopregnanolone.

 

Unlock insights into the Postpartum Depression Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Postpartum Depression Market Forecast. Click here @ Postpartum Depression Market Drivers and Barriers

 

Postpartum Depression Market Outlook

Antidepressants, such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR (Fluvoxamine Maleate), and Paxil CR (paroxetine) form the mainstay in the Postpartum Depression treatment. Although these drugs are approved for treating depression-related disorders such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), treatment-resistant depression (TRD), etc., they are being used as off-label drugs for the treatment of PPD. The type of medication prescribed by the doctors largely depends on the set of symptoms, severity and the specific type of PPD the patient is suffering from. The primary concern about antidepressants is the uncertainty in the outcomes and their side effects on new born due to breastfeeding. Though antidepressants are not necessarily a permanent cure for PPD, they are an important aspect of managing depression symptoms and restoring quality of life.

 

Scope of the Postpartum Depression Market Report

  • Coverage- 7MM
  • Study Period- 2020-2034
  • Postpartum Depression Companies- Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, and others.
  • Postpartum Depression Pipeline Therapies- SAGE-217/BIIB-125, Ganaxolone, LPCN 1154, BRII-296, and others.
  • Postpartum Depression Market Dynamics: Postpartum Depression Market Drivers and Barriers
  • Postpartum Depression Market Access and Reimbursement, and Unmet Needs

 

Gain a strategic edge in the Postpartum Depression Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Postpartum Depression Market Forecast. Click here to lead in advancements @ Postpartum Depression Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Report Introduction

3. Postpartum Depression Market Overview at a Glance

4. Executive Summary of Postpartum depression (PPD)

5. Key events

6. Disease Background and Overview

7. Treatment and Management

8. Methodology

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed Therapies

12. Emerging Therapies

13. Postpartum Depression (PPD): Seven Major Market Analysis

14. KOL Views

15. SWOT Analysis

16. Unmet Needs

17. Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Postpartum Depression Therapeutics Market Size in the 7MM was ~USD 260 Million in 2023, is expected to grow by 2034, and estimates DelveInsight

US Electric Motors Market Share Expected to Reach $42.07 billion by 2029

The global US electric motors market share is expected to grow from estimated $31.06 billion in 2024 to $42.07 billion by 2029, at a CAGR of 6.3% during the forecast period.

The global US Electric Motors Market share is expected to grow from USD 31.06 billion in 2024 to USD 42.07 billion by 2029, at a CAGR of 6.3% during 2024-2029. The electric motors market in US is growing as energy efficiency solutions become increasingly visible and demanded across all segments. Besides contributing renewable energy systems and electric vehicles to smart manufacturing, the country’s electric motors are quite linked to the sustainability goals of the nation. Among the benefits reapable from the use of electric motors are reduction of energy, cost savings in operations, and the elimination of emissions from the overall energy portfolio. The adoption is further assisted through government policies and incentives that stimulate energy-efficient technologies. Innovations in motor technologies such as brushless DC motors and variable frequency drives have improved performance, reliability, and flexibility of applications hence promoting the growth of the market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=717

According to type, the US Electric motors market is classified as follows- AC motors, and DC motors. In modern buildings, AC motors are common in industrial and commercial applications. They are very durable and require minimum maintenance and efficiency very high. They are mostly used in heating, ventilation, and air conditioning, pumping systems and conveyors. These are some of the primary reasons for which the surge in renewable energy systems such as wind turbines will further increase the demand for AC motors. On the other hand, the DC motors majorly serve applications needing high accuracy and variable-speed classes such as robotics and electric vehicles aside from mobile equipment. It is the growing market for electric cars and developments in battery technology that is critical for the growth of the DC motor industry. Innovations like variable frequency drives and the IoT will prove beneficial for both motor types by further putting emphasis in better control, monitoring, and efficiency. All in all, demand is projected to increase in the market based on energy conservation and advances in technology.

The end-user segment of the US Electric motors market is made up of industrial, residential, commercial, transportation, and agriculture.  In the industrial sector, the use of electric motors in automation for manufacturing processes, and more energy-efficient operations now demands efficient motors that will be used in conveyors, pumps, and robotic systems. The commercial field will thrive with more and more motors being used for HVAC systems, elevators, and escalators in pursuit of urbanization and energy efficiency.  In the residential sector, common consumers adopt washing machines, refrigerators, and HVAC units that promise energy efficiency as affordable benefits with common views on environmental threats. On the other hand, the transportation segment is growing rapidly because of a rapid increase in the deployment of electric vehicles. In this respect, advanced electric motors have a major role in the future with respect to improving the efficiency, performance, and range of electric vehicles. In agriculture, motors are used mainly to power irrigation systems, sets of grain handling equipment, and automated feeder systems. The electric motor market in the US has achieved significant growth in nearly all of its end-use sectors because of technological advances and an improvement in the demand for engine works brought by the sustainability drive and changing needs of the industries.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=717

Major players in the US Electric Motors Market include Regal Rexnord Corporation (US), AMETEK, Inc. (US), Allied Motion Technologies (US), Rockwell Automation (US), Franklin Electric (US), ABB (Switzerland), Siemens (Germany), and Nidec Corporation (Japan) among others. These companies focus on innovation, product development, and strategic partnerships to cater to the growing demand for elevator component market.

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report. 

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets™ INC.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA: +1-888-600-6441 

Email: newsletter@marketsandmarkets.com

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/electric-motor-market-alternative-fuel-vehicles-717.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: US Electric Motors Market Share Expected to Reach $42.07 billion by 2029

FearLS Launches Kickstarter Campaign to Empower Bold Living Through Faith-Inspired Athleisure Apparel

FearLS, a bold new athleisure brand, is thrilled to announce the launch of its Kickstarter campaign, set to run from December 11, 2024, to January 10, 2025. With a funding goal of $15,465, the campaign aims to bring the debut FearLS collection to life, offering faith-driven, high-quality apparel designed to inspire confidence, courage, and hope. FearLS stands for more than clothing—it’s a movement that empowers individuals to face life’s challenges through unwavering faith and bold living.

At the heart of FearLS is a mission to inspire people to overcome fear and live courageously, grounded in faith. The brand’s debut collection features scripture-inspired designs that serve as daily reminders of God’s promises and the strength that comes from trusting in Him. Each piece blends style, comfort, and functionality, making it not just a wardrobe staple but also a meaningful tool for encouragement.

“FearLS isn’t just clothing—it’s a daily declaration that fear has no place where faith thrives,” said Edward Campiani, founder of FearLS. “Each piece of FearLS apparel is crafted to remind you that God’s promises are greater than any fear, empowering you to face life with courage.”

FearLS was born out of a desire to address the tangible struggles of anxiety, doubt, and uncertainty that so many individuals experience. Recognizing how fear often holds people back from living boldly, the brand was created to deliver apparel that is as uplifting as it is functional. Beyond offering stylish designs, FearLS is a call to action—encouraging individuals to step into their lives with faith, hope, and strength.

A portion of proceeds from FearLS will go toward supporting nonprofit initiatives, amplifying the brand’s mission to build a fearless community rooted in faith. By partnering with organizations that share its values, FearLS seeks to inspire hope and positively impact communities in need.

“FearLS began with a simple but powerful idea: to help people face their fears through faith,” Campiani added. “We wanted to create something that could serve as a tangible reminder that fear doesn’t have the final word. By wearing FearLS apparel, supporters join a mission to spread hope, uplift others, and share the power of God’s love.”

FearLS has ambitious plans for the future, including expanding its product line to offer even more faith-inspired apparel and accessories. The brand envisions becoming a global movement of courage and community, where stories of resilience and faith are shared and celebrated. As it grows, FearLS remains committed to fostering a community that empowers individuals to embrace life boldly and purposefully.

The Kickstarter campaign marks a significant first step for FearLS. By supporting this initiative, backers not only help bring the inaugural collection to life but also contribute to a larger mission of inspiring faith, courage, and hope.

To stay updated, visit the Kickstarter campaign at Kickstarter Link and follow FearLS on Instagram at @fearlssfit. Updates about the campaign and brand progress will also be shared on the soon-to-launch official website, www.fearlssfit.com.

Media Contact
Company Name: FearLS
Contact Person: Edward Campiani
Email: Send Email
City: Chatsworth
State: California
Country: United States
Website: www.fearlssfit.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: FearLS Launches Kickstarter Campaign to Empower Bold Living Through Faith-Inspired Athleisure Apparel

Nontuberculous Mycobacterial Infections Treatment Market Size was ~USD 360 Million in the US in 2023, is expected to grow by 2034 | DelveInsight

DelveInsight’s “Nontuberculous Mycobacterial Infections Market Insights, Epidemiology, and Market Forecast–2034” report delivers an in-depth understanding of NTM Infections, historical and forecasted epidemiology, as well as the NTM Infections market trends in the United States.

 

Explore the intricate details of the Nontuberculous Mycobacterial Infections Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Nontuberculous Mycobacterial Infections Market Forecast. Click here to stay ahead in healthcare innovation @ Nontuberculous Mycobacterial Infections Market Size

 

Key Takeaways from the Non-Tuberculous Mycobacterial Infections Market Report

  • The Non-Tuberculous Mycobacterial Infections market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • Based on DelveInsight’s epidemiology model, the total number of diagnosed prevalent cases of Nontuberculous Mycobacterial Infections in the US was around 108,000 in 2023, with an anticipated increase during the forecast period (2024–2034) due to various contributing factors.
  • In 2023, NTM Infections in the US showed a higher prevalence in females compared to males. Females represented about 68% of the total diagnosed prevalent cases of Nontuberculous Mycobacterial Infections, while males accounted for around 32%.
  • In 2023, M. avium was the most common species responsible for Nontuberculous Mycobacterial Infections in the US, accounting for nearly 76 thousand diagnosed prevalent cases. It was followed by M. abscessus with around 14 thousand cases, and other species like M. kansasii and M. xenopi, which contributed to approximately 18 thousand cases.
  • In 2023, the US had about 86 thousand diagnosed prevalent cases of Nontuberculous Mycobacterial Infections of the pulmonary type and approximately 22 thousand cases of the extrapulmonary type
  • As per Shanmugam et al., about 1·5 million people died from TB, and nearly 10 million people fall ill with Mtb infection worldwide, of which only 6·4 million were diagnosed and officially reported
  • Among the 7MM countries. The most prevalent cases of Non- Tuberculous Mycobacterial infections were recorded in the United States.
  • The leading Non- Tuberculous Mycobacterial Infections Companies such as Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune, and others
  • Promising Non- Tuberculous Mycobacterial Infections Therapies such as SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107, and others

 

Navigate the complexities of the Nontuberculous Mycobacterial Infections Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Nontuberculous Mycobacterial Infections Market Forecast. Click here to get more insights @ Nontuberculous Mycobacterial Infections Treatment Market

 

Non-Tuberculous Mycobacterial Infections Epidemiology Segmentation in the 7MM

  • Total Prevalence of Non- Tuberculous Mycobacterial Infections
  • Prevalent Cases of Non- Tuberculous Mycobacterial Infections by severity
  • Gender-specific Prevalence of Non- Tuberculous Mycobacterial Infections
  • Diagnosed Cases of Episodic and Chronic Non- Tuberculous Mycobacterial Infections

 

Download the report to understand which factors are driving Non-Tuberculous Mycobacterial Infections epidemiology trends @ Non-Tuberculous Mycobacterial Infections Prevalence

 

Nontuberculous Mycobacterial Infections Marketed Drugs

  • ARIKAYCE (amikacin liposome inhalation suspension): Insmed

ARIKAYCE is the first FDA-approved therapy indicated for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function. Insmed’s proprietary PULMOVANCE liposomal technology enables the delivery of amikacin directly to the lungs, where lung macrophages take it up, targeting the site of infection. This approach prolongs the release of amikacin in the lungs while limiting systemic exposure. ARIKAYCE is administered once daily using the Lamira Nebulizer System manufactured by PARI Pharma GmbH.

 

Nontuberculous Mycobacterial Infections Emerging Drugs

  • Epetraborole: AN2 Therapeutics

Epetraborole (EBO), developed by AN2 Therapeutics, is a novel, once-daily, orally administered investigational treatment for patients with chronic NTM lung disease. Epetraborole is a boron-containing small molecule inhibitor of bacterial leucyl-tRNA synthetase, or LeuRS, an enzyme that catalyzes the attachment of leucine to transfer RNA, or tRNA, molecules, an essential step in protein synthesis. Epetraborole forms a complex with a tRNALEU molecule, trapping the terminal ribonucleotide of tRNALEU in the editing site of the enzyme, which prevents the synthetic site from attaching leucine to tRNALEU thus shutting down tRNA leucylation and leading to a block in protein synthesis. Currently, the drug is in Phase II/III of clinical development for the treatment of patients with NTM lung disease. AN2 Therapeutics intends to expand the indication targeted by epetraborole by pursuing development in other mycobacterial diseases, including treatment-naïve MAC lung disease. AN2 Therapeutics also intends to conduct trials in which they plan to incorporate epetraborole as part of first-line combination treatment for treatment-naive patients with NTM lung disease and M. abscessus lung infections.

 

  • MNKD-101 (Clofazimine Inhalation Suspension): Mannkind Corporation

MNKD-101, a nebulized formulation of clofazimine, is being developed for the treatment of severe chronic and recurrent pulmonary infections, including NTM lung disease. An orally inhaled formulation of clofazimine is anticipated to offer several clinical advantages over the current solid oral dosage form of this drug. MNKD-101 has been designated as both an orphan drug and a qualified infectious disease product by the US FDA for the treatment of pulmonary NTM infections. Mannkind is also assessing the feasibility of developing a dry-powder formulation of clofazimine using Mannkind’s technosphere formulation technology. MNKD-101 is designated with fast-track designation by the US FDA for the treatment of NTM lung infections. Mannkind intends to commence a Phase III registration study of MNKD-101 in the US in the second quarter of 2024.

 

  • SPR720 (Fobrepodacin): Spero Therapeutics

SPR720, developed by Spero Therapeutics, is a broad-spectrum oral antibiotic designed to treat NTM pulmonary disease. SPR720 employs a novel mechanism and has no known cross-resistance with marketed antibiotics. SPR720 has demonstrated a broad spectrum of activity in preclinical studies against the most common organisms causing NTM infections, including M. avium complex, or MAC, M. kansasii, and M. abscessus. SPR720 is applicable to both nonrefractory and refractory patients.

 

Unlock insights into the Nontuberculous Mycobacterial Infections Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Nontuberculous Mycobacterial Infections Market Forecast. Click here @ Nontuberculous Mycobacterial Infections Market Drivers and Barriers

 

Non- Tuberculous Mycobacterial Infections Therapies and Companies

  • SPR720: Spero Therapeutics
  • Molgramostim: Savara Pharmaceuticals
  • Thiolanox (Nitric Oxide): Mallinckrodt Inc.
  • NUZYRA (omadacycline): Paratek Pharmaceuticals Inc.
  • CYT 107: Revimmune

 

Scope of the Non- Tuberculous Mycobacterial Infections Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM
  • Non-Tuberculous Mycobacterial Infections Companies: Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune, and others
  • Non-Tuberculous Mycobacterial Infections Therapies: SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107, and others
  • Non-Tuberculous Mycobacterial Infections Therapeutic Assessment: Non- Tuberculous Mycobacterial Infections current marketed and Non- Tuberculous Mycobacterial Infections emerging therapies
  • Non-Tuberculous Mycobacterial Infections Market Dynamics: Non- Tuberculous Mycobacterial Infections market drivers and Non- Tuberculous Mycobacterial Infections market barriers
  • Non- Tuberculous Mycobacterial Infections Unmet Needs, KOL’s views, Analyst’s views, Non- Tuberculous Mycobacterial Infections Market Access and Reimbursement

 

Gain a strategic edge in the Nontuberculous Mycobacterial Infections Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Nontuberculous Mycobacterial Infections Market Forecast. Click here to lead in advancements @ Nontuberculous Mycobacterial Infections Clinical Trials Assessment

 

Table of Contents

1. Non- Tuberculous Mycobacterial Infections Market Report Introduction

2. Executive Summary for Non- Tuberculous Mycobacterial Infections

3. SWOT analysis of Non- Tuberculous Mycobacterial Infections

4. Non- Tuberculous Mycobacterial Infections Patient Share (%) Overview at a Glance

5. Non- Tuberculous Mycobacterial Infections Market Overview at a Glance

6. Non- Tuberculous Mycobacterial Infections Disease Background and Overview

7. Non- Tuberculous Mycobacterial Infections Epidemiology and Patient Population

8. Country-Specific Patient Population of Non- Tuberculous Mycobacterial Infections

9. Non- Tuberculous Mycobacterial Infections Current Treatment and Medical Practices

10. Non- Tuberculous Mycobacterial Infections Unmet Needs

11. Non- Tuberculous Mycobacterial Infections Emerging Therapies

12. Non- Tuberculous Mycobacterial Infections Market Outlook

13. Country-Wise Non- Tuberculous Mycobacterial Infections Market Analysis (2020–2034)

14. Non- Tuberculous Mycobacterial Infections Market Access and Reimbursement of Therapies

15. Non- Tuberculous Mycobacterial Infections Market Drivers

16. Non- Tuberculous Mycobacterial Infections Market Barriers

17. Non- Tuberculous Mycobacterial Infections Appendix

18. Non- Tuberculous Mycobacterial Infections Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Nontuberculous Mycobacterial Infections Treatment Market Size was ~USD 360 Million in the US in 2023, is expected to grow by 2034 | DelveInsight

Lucintel Forecasts Access Control as a Service Market to Reach $3 billion by 2030

“According to the recent study the Access Control as a Service Market is projected to reach an estimated $3 billion by 2030 from $1.0 billion in 2023, at a CAGR of 15.0% from 2023 to 2030”
According to the recent study the Access Control as a Service Market is projected to reach an estimated $3 billion by 2030 from $1.0 billion in 2023, at a CAGR of 15.0% from 2023 to 2030

According to the recent study the Access Control as a Service Market is projected to reach an estimated $3 billion by 2030 from $1.0 billion in 2023, at a CAGR of 15.0% from 2023 to 2030. Growth in this market is primarily driven by increasing uses of cloud computing platforms and IoT technology, growing demand for cloud based hosted and managed services and rising adoption of electronic security products in access control as a services market.

Browse 80 figures / charts and 74 tables in this 150 -page report to understand trends, opportunities and forecast in access control as a service market by end use industry (commercial, manufacturing and industrial, government bodies, residential, transportation, healthcare, education, and utilities), service (hosted, managed, and hybrid), deployment (public cloud, private cloud, and hybrid cloud). and region (North America, Europe, APAC and the Rest of the World).

Lucintel forecasts that managed service will remain the largest service type and it is also expected to witness the highest growth over the forecast period due to the increasing demand in organizations to secure data and as adding and deleting access rights and credentials.

Within the access control as a service market, public cloud will remain the largest segment by deployment type and private cloud is also expected to witness the highest growth over the forecast period due to growing demand from end user such as single organization, managed, and operated by the organization, a third party, or some combination of them.

Download sample by clicking on Access Control as a Service Market

North America will remain the largest region due to high adoption of advanced and IoT based cloud computing to minimizing risk for a business or organization. APAC is expected to witness the highest growth over the forecast period supported by increasing uses of access control as service in commercial, manufacturing and industrial sectors.

Brivo Inc., Cloud structure Inc, Assa Abloy Ab, Dormakaba, Honeywell Security are the major suppliers in the access control as a service providers.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com

About Lucintel

At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.

Contact: Roy Almaguer Lucintel Dallas, Texas, USA Email: roy.almaguer@lucintel.com Tel. +1 972 636 5056

Explore Our Latest Publications

Arc Welding Fume Extraction Equipment Market

Phase Change Material Market

Saudi Arabian Polyolefin Film Market

Hot Rolled Coil Steel Market

Liquid Coating Market

Packaging Additives Market

 

 

Media Contact
Company Name: Lucintel
Contact Person: Roy Almaguer
Email: Send Email
Phone: 972.636.5056
Address:8951 Cypress Waters Blvd., Suite 160
City: Dallas
State: TEXAS
Country: United States
Website: https://www.lucintel.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lucintel Forecasts Access Control as a Service Market to Reach $3 billion by 2030

Poulson Family Launches Fundraising Campaign to Support Disabled Veteran Battling Late-Stage Colorectal Cancer

The Poulson Family has launched a heartfelt fundraising campaign to support Andrew Poulson, a disabled veteran and loving father, in his battle against late-stage colorectal cancer. The campaign aims to raise essential funds to reunite Andrew’s family.

Diagnosed earlier this year, Andrew’s late-stage colorectal cancer has left him immobilized and in constant pain. His treatment at MD Anderson Cancer Center includes a rigorous regimen of chemotherapy and radiation. The presence of his family has become crucial not only for his emotional resilience but also for his physical recovery during this challenging period.

“Cancer is not just a personal battle; it’s a family’s fight. We are determined to stand by Andrew in his most difficult time, but we can’t do it alone,” said Jeciel Poulson, Andrew’s spouse. “Reuniting our family will provide the strength and love he needs to face this journey.”

The campaign seeks to cover costs associated with bringing Andrew’s family to the U.S. The family has faced significant financial and emotional challenges since Andrew’s diagnosis, relying on community support to bridge the gap. A disabled veteran who has dedicated much to his country, Andrew now turns to the kindness and generosity of the community for strength in his greatest fight.

Beyond the immediate need for family reunification, the campaign highlights the broader struggles faced by many veterans who battle severe health challenges without adequate support systems. Andrew’s story is a poignant reminder of the sacrifices made by servicemen and women and the vital importance of rallying as a community to support them in their time of need. The campaign serves as a beacon of hope, showcasing how collective effort can provide not just financial relief but also emotional sustenance for families in crisis.

“I’ve faced many challenges as a veteran, but this is the toughest fight of my life,” said Andrew Poulson. “Having my family with me will be the strength I need to push through.”

The Poulson Family’s campaign underscores the vital role of community and familial support in overcoming life’s greatest challenges. Donations will directly contribute to travel arrangements and the family’s ability to support Andrew during his treatment.

To support Andrew’s fight and contribute to this campaign, visit the official GoFundMe page at https://gofund.me/1554d65f.

Updates and additional information can be found on the campaign’s Facebook page: Poulson Family – Dad with Cancer.

About Company:

The Poulson Family is a devoted unit committed to reuniting and providing unwavering support to Andrew Poulson in his battle against cancer. This campaign reflects the enduring power of love, family, and community in overcoming adversity.

Media Contact
Company Name: The Poulson Family
Contact Person: Andrew Poulson
Email: Send Email
City: Queen Creek
State: Arizona
Country: United States
Website: gofund.me/1554d65f

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Poulson Family Launches Fundraising Campaign to Support Disabled Veteran Battling Late-Stage Colorectal Cancer

Urgent Fundraising Campaign Launched to Save Gurdarshan Salh’s Life

An urgent fundraising campaign has been launched to provide life-saving medical care for Gurdarshan Salh, a devoted husband and father who is battling heart failure and valve leakage. Organized by Sukhdev Singh, a family member in Calgary, the initiative aims to raise critical funds to cover Gurdarshan’s mounting hospital expenses, which have reached a staggering $25,000 per day.

Gurdarshan, a hardworking and compassionate individual, traveled to Canada to visit family, bringing joy and warmth to those around him. However, his visit took a tragic turn when he was rushed to the hospital with severe heart issues. After over a week of intensive care, Gurdarshan remains in the ICU, relying on costly medications and treatments to stabilize his condition.

This life-threatening medical crisis has not only shaken Gurdarshan’s immediate family but also deeply affected his wife and young son, who remain in India, grappling with this unexpected and heartbreaking situation from afar. The family’s emotional burden is compounded by the overwhelming financial strain of his treatment.

“We are racing against time to save Gurdarshan’s life,” says Sukhdev Singh, who is spearheading the campaign. “The cost of care is astronomical, but we believe in the power of community and the kindness of others to help us through this crisis.”

The fundraising campaign, hosted on GoFundMe, seeks to rally support from the public to ensure Gurdarshan receives the care he desperately needs. Donations will directly fund his ICU stay, medications, and other essential medical expenses.

The Salh family is appealing to the community to come together during this difficult time. “Every contribution, no matter the size, brings us closer to giving Gurdarshan a chance at recovery,” says Singh. “If you’re unable to donate, even sharing this campaign can create a ripple effect of hope and support.”

Gurdarshan’s story is a powerful reminder of the fragility of life and the strength of collective action. His family remains hopeful that, with the help of compassionate individuals, they can overcome this crisis and bring Gurdarshan back home to his loved ones.

To contribute to this life-saving cause, visit the official GoFundMe page at https://gofund.me/c7645769. Donations are secure and go directly toward covering medical expenses. Sharing the campaign on social media and with personal networks is also a vital way to extend support.

Media Contact
Company Name: Sukhdev Singh Fundraising Campaign
Contact Person: Sukhdev Singh
Email: Send Email
City: Calgary
State: Alberta
Country: Canada
Website: gofund.me/c7645769

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Urgent Fundraising Campaign Launched to Save Gurdarshan Salh’s Life

Fungicides Market Growth Drivers, Opportunities, Key Segments, Leading Players, Emerging Trends, Recent Developments, and Forecast – 2029

“MarketsandMarkets™”
Fungicides Market by Type (Chemical and Biological), Mode of Action (Contact and Systemic), Formulation (Liquid and Dry), Mode of Application (Foliar Spray, Seed Treatment, and Soil Treatment), Crop Type and Region – Global Forecast to 2029

The global fungicides market is valued at USD 23.9 billion in 2024 and is projected to grow to USD 32.3 billion by 2029, registering a CAGR of 6.2% during the forecast period. One of the key drivers behind this growth is the increasing global demand for food, which necessitates higher agricultural productivity to support the expanding world population. Additionally, advancements in fungicide formulations—emphasizing improved potency, eco-friendliness, and targeted application—are further fueling market expansion. Government initiatives promoting sustainable agricultural practices and the rising use of fungicides in non-agricultural sectors, such as turf management and ornamental plants, also contribute significantly to the market’s upward trajectory.

Fungicides Market

Fungicides Market Driver: Climate Change and Rising Crop Disease Infestation

Shifting weather patterns and rising global temperatures have created favorable conditions for the proliferation of pests and fungal diseases, increasing crop vulnerability across regions. These challenges pose significant risks to agricultural productivity and profitability, necessitating the use of fungicides as a critical component of modern crop protection strategies. The prevalence of fungal pathogens has led to a sharp increase in demand for fungicidal solutions that help maintain crop health and stabilize yields.

Fungicides Opportunities: Growing Demand for Biological Fungicides

The rising demand for bio-fungicides presents a promising growth opportunity in the global fungicides market. Increasing consumer awareness and regulatory efforts to promote sustainable farming practices are driving the adoption of these environmentally friendly alternatives to conventional chemical fungicides. Derived from natural sources, bio-fungicides align with the goals of organic and sustainable agriculture by reducing the environmental impact of crop protection. These solutions appeal to health-conscious consumers seeking food produced with minimal synthetic inputs, further supporting their market potential.

Crop Segment Highlight: Dominance of Cereals & Grains

The cereals and grains segment holds the largest share of the fungicides market, driven by their critical role in global food security. Staple crops such as wheat, rice, and corn are widely cultivated across diverse climates and are particularly susceptible to fungal diseases, which can significantly impact yield and quality. The economic importance of these crops compels farmers to invest heavily in fungicides to protect their harvests. Furthermore, the large-scale cultivation of these crops necessitates continuous and uniform fungicide application, reinforcing the segment’s leading position in the market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=356

Formulation Trends: Liquid Fungicides Leading Growth

The liquid fungicide segment is anticipated to grow at the fastest rate during the forecast period, thanks to its ease of application and ability to provide uniform coverage. Liquid formulations can be easily mixed with water and other chemicals, ensuring precise dosing and efficient distribution across large farming areas. Their compatibility with various application methods, such as sprayers and irrigation systems, enhances their effectiveness in crop protection. Additionally, liquid fungicides adhere well to plant surfaces, offering prolonged protection against fungal infections.

Regional Insights: Asia Pacific Leads the Market

The Asia Pacific region holds the largest share of the fungicides market, driven by extensive agricultural activities, rapid population growth, and the pressing need for food security. Major agricultural producers like China, India, and Japan contribute significantly to global food supply chains. However, the diverse climatic conditions in this region make crops highly vulnerable to fungal diseases, boosting the demand for effective fungicide solutions. Increased awareness among farmers about the benefits of fungicides, coupled with supportive government policies aimed at enhancing agricultural productivity, further drives market growth in the region. As modernization of farming practices continues, the Asia Pacific region is expected to maintain its dominant position in the fungicides market.

Leading Fungicides Manufacturers:

Key players in this market include BASF SE (Germany), Bayer AG (Germany), Syngenta Group (Switzerland), UPL (India), Corteva (US), FMC Corporation (US), Nufarm (Australia), Sumitomo Chemical Co., Ltd. (Japan), NIPPON SODA CO, LTD. (Japan), Gowan Company (US),   American Vanguard Corporation (US), Koppert (Netherlands), KUMIAI CHEMICAL INDUSTRY CO., LTD. (Japan), Albaugh LLC (US), and Sipcam Oxon Spa (Italy).

Bayer AG (Germany)

Bayer AG is a German multinational pharmaceutical and biotechnology company and ranks among the largest pharmaceutical companies globally. Bayer sells its products through its pharmaceuticals, consumer health, and crop science business segments. Fungicides are a part of the agricultural segment. Flint, Fox, Luna, Sonata, and Mikal are some brands in the fungicides category. Bayer AG is present in more than 120 countries worldwide. Geographically, it is primarily based in Europe and highly active in North America, Latin America, Africa, the Middle East, and the Asia Pacific.

In July 2024, Bayer launched in Brazil the Valpura fungicide, featuring the active ingredient bixafen. With this new kind of action, Valpura is able to offer high efficiency and long-lasting disease control. According to Bayer, the launch will raise the productive potential for potato, tomato, grape, and apple crops.

BASF SE (Germany)

BASF SE is a chemical-based company that does all the production, marketing, and selling of chemicals, plastics, crop protection products, and various performance products. The product line includes solvents, paints, food additives, fungicides, herbicides, and various sorts of chemicals. BASF SE has 11 divisions, which are condensed into 7 business models: chemicals, materials, industrial solutions, surface technologies. nutrition & care, agricultural solution and others. The company offers fungicides under the agricultural solutions segment. It provides fungicides under brands such as Cabrio, Caramba, Pristine, and Stamina. The company operates through a huge network of its manufacturing facilities across the globe. The base is in Europe, Asia Pacific, South America, Africa, the Middle East, and North America.

In March 2024, BASF announced that it is investing in new fermentation plant for biologic and biotechnologically based crop protection products at the Ludwigshafen site. The production facility will start up in the second half of 2025, producing high-value products for farmers, such as biological fungicides and seed treatments.

Request Sample pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=356

About MarketsandMarkets™

MarketsandMarketsTM has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

 

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/fungicides-356.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fungicides Market Growth Drivers, Opportunities, Key Segments, Leading Players, Emerging Trends, Recent Developments, and Forecast – 2029

AIRE launches AIRE Software to streamline Real Estate Feasibility Studies preparation

AIRE has introduced AI-powered software to deliver feasibility study reports in five business days, enabling faster real estate decision-making.

AIRE, a leading PropTech innovator in the Middle East and Africa, has launched an advanced AI-powered software that enables its team to deliver feasibility study reports for residential, hospitality, retail, and office developments in just five business days. This solution marks a significant step forward in applying artificial intelligence to streamline traditionally time-intensive processes in real estate development.

Historically, the preparation of feasibility studies—a crucial step for developers, investors, and real estate professionals to assess project viability—has taken up to six weeks. AIRE’s new platform reduces this timeframe by nearly 90%, giving clients a vital edge in a competitive and fast-moving market.

“Our AI-powered solution is more than just a time-saver; it empowers stakeholders to make smarter, faster, and data-driven decisions with unparalleled accuracy,” said Simon Ardonceau, founder and CEO of AIRE. “By combining advanced technology with our deep industry expertise, we are reshaping how real estate projects are planned and executed across the Middle East and Africa.”

The platform uses artificial intelligence to process vast datasets, analyze market trends, and deliver actionable insights tailored to the specific needs of each project. Whether for residential complexes, luxury hotels, retail hubs, or office spaces, AIRE ensures that clients receive detailed, high-quality reports without the prolonged wait times associated with traditional methods.

With a mission to accelerate innovation in real estate, AIRE’s latest offering demonstrates the transformative potential of PropTech in driving efficiency and sustainability. By enabling faster feasibility assessments, the company is helping its clients reduce project risks while supporting the creation of more innovative, more resilient urban developments across the region.

This innovative approach also aligns with the growing demand for technology-driven solutions to improve operational efficiency, minimize delays, and provide highly accurate insights. AIRE aims to set new industry benchmarks by introducing tools that help stakeholders make informed decisions in record time.

AIRE invites developers, investors, and professionals to experience the future of real estate decision-making. 

To learn more about this cutting-edge technology, visit https://www.airealestate.org/airesoftware

Follow AIRE on Social Media:

YouTube: https://youtu.be/ARsfRPi7rD4?si=k5Ve-J4uxEK26trw 

LinkedIn: https://www.linkedin.com/company/airealestate/

 

Media Contact
Company Name: AIRE
Contact Person: Peter Mungla
Email: Send Email
City: Dubai
Country: Saudi Arabia
Website: www.airealestate.org/airesoftware

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AIRE launches AIRE Software to streamline Real Estate Feasibility Studies preparation